Aspire Biopharma Holdings, Inc. (ASBP): Form 8-K filed 2026-08-10

Items reported

Item 1.01: Entry into a Material Definitive Agreement
The company signed a material agreement outside the ordinary course of business, or materially amended one. Typical examples are credit agreements, merger agreements, large supply or licensing contracts and financing arrangements.
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
The company became obligated under a material direct financial obligation, such as a loan, notes offering or credit facility draw, or under a material off-balance sheet arrangement.
Item 3.02: Unregistered Sales of Equity Securities
The company sold equity securities in a transaction not registered under the Securities Act, such as a private placement, above a size threshold.
Item 7.01: Regulation FD Disclosure
The company is making information public under Regulation FD, which requires broad public disclosure of material information shared with certain market participants. Investor presentations and press releases are common. Like Item 2.02, this information is generally "furnished" rather than "filed".
Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.

This page lists what the filing reports; it does not summarize or interpret it. Read the original documents on SEC EDGAR. How to read an 8-K.